missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ PD-L1/4-1BBL Humanized Biosimilar Recombinant Human Monoclonal Antibody
PD-L1/4-1BBL Biosimilar Recombinant Monoclonal Antibody
Marke: Invitrogen™ MA560148
Dieser Artikel kann nicht zurückgegeben werden.
Rückgaberichtlinie anzeigen
Beschreibung
PD-L1/4-1BBL Biosimilar Recombinant Monoclonal Antibody for SPR, Flow, ELISA, Functional
PD-L1 (Programmed Death-Ligand 1) is a transmembrane protein encoded by the CD274 gene located on chromosome 9p24.1. It is expressed on various cell types, including tumor cells, where it plays a critical role in immune evasion by binding to its receptor PD-1 on T cells, thus inhibiting T cell function and allowing tumor cells to escape immune surveillance. PD-L1 has also been implicated in promoting tumor growth, progression, and radioresistance. On the other hand, 4-1BBL (4-1BB ligand) is a member of the tumor necrosis factor (TNF) superfamily expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages. It is encoded by the TNFSF9 gene on chromosome 19p13.3. 4-1BBL binds to its receptor 4-1BB (CD137) on T cells, providing a co-stimulatory signal that enhances T cell proliferation and survival, as well as cytokine production. The interaction between 4-1BBL and 4-1BB is crucial in the regulation of immune responses, particularly in cancer immunotherapy, where it is leveraged to boost anti-tumor immunity.
Spezifikation
| PD-L1/4-1BBL Humanized Biosimilar | |
| Recombinant Monoclonal | |
| Unconjugated | |
| Human | |
| 1 mg | |
| Primary | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Lyophilized |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| 1 mg/mL | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Protein A | |
| RUO | |
| Human | |
| Antibody | |
| VHH |
Berichtigung von Produktinhalten
Bitte geben Sie uns Ihr Feedback zu den Produktinhalten, indem Sie das folgende Formular ausfüllen.
Name des Produkts
Haben Sie Verbesserungsvorschläge?Übermitteln Sie eine inhaltliche Korrektur